Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 185

1.

Renal Drug Transporters and Drug Interactions.

Ivanyuk A, Livio F, Biollaz J, Buclin T.

Clin Pharmacokinet. 2017 Aug;56(8):825-892. doi: 10.1007/s40262-017-0506-8. Review.

PMID:
28210973
2.

Biases affecting injected doses of an experimental drug during clinical trials.

Perrottet N, Brunner-Ferber F, Grouzmann E, Spertini F, Biollaz J, Buclin T, Widmer N.

Trials. 2016 Jul 16;17(1):321. doi: 10.1186/s13063-016-1463-5.

3.

Pregnancy outcome following maternal exposure to pregabalin may call for concern.

Winterfeld U, Merlob P, Baud D, Rousson V, Panchaud A, Rothuizen LE, Bernard N, Vial T, Yates LM, Pistelli A, Ellfolk M, Eleftheriou G, de Vries LC, Jonville-Bera AP, Kadioglu M, Biollaz J, Buclin T.

Neurology. 2016 Jun 14;86(24):2251-7. doi: 10.1212/WNL.0000000000002767. Epub 2016 May 18.

PMID:
27194385
4.

Free and total plasma levels of lopinavir during pregnancy, at delivery and postpartum: implications for dosage adjustments in pregnant women.

Fayet-Mello A, Buclin T, Guignard N, Cruchon S, Cavassini M, Grawe C, Gremlich E, Popp KA, Schmid F, Eap CB, Telenti A, Biollaz J, Decosterd LA, Martinez de Tejada B; Swiss HIV Cohort Study; Mother & Child HIV Cohort Study.

Antivir Ther. 2013;18(2):171-82. doi: 10.3851/IMP2328. Epub 2012 Aug 22.

PMID:
22914504
5.

Effect of population-based screening on breast cancer mortality.

Riva C, Biollaz J, Foucras P, Junod B, Nicot P, Spinosa JP.

Lancet. 2012 Apr 7;379(9823):1296; author reply 1298. doi: 10.1016/S0140-6736(12)60548-0. No abstract available.

PMID:
22483024
6.

Cell disposition of raltegravir and newer antiretrovirals in HIV-infected patients: high inter-individual variability in raltegravir cellular penetration.

Fayet Mello A, Buclin T, Franc C, Colombo S, Cruchon S, Guignard N, Biollaz J, Telenti A, Decosterd LA, Cavassini M.

J Antimicrob Chemother. 2011 Jul;66(7):1573-81. doi: 10.1093/jac/dkr151. Epub 2011 Apr 19.

PMID:
21508009
7.

Letter to the editor response to the article of Luisa Lina Villa HPV prophylactic vaccination: the first years and what to expect from now, in press.

Spinosa JP, Riva C, Biollaz J.

Cancer Lett. 2011 May 1;304(1):70. doi: 10.1016/j.canlet.2011.01.024. Epub 2011 Feb 19. No abstract available.

PMID:
21339044
8.

[Pharmacovigilance update].

Livio F, Biollaz J, Buclin T.

Rev Med Suisse. 2011 Jan 12;7(277):71-4. French.

PMID:
21309181
9.

Who is in charge of assessing therapeutic drug monitoring? The case of imatinib.

Buclin T, Widmer N, Biollaz J, Decosterd LA.

Lancet Oncol. 2011 Jan;12(1):9-11. doi: 10.1016/S1470-2045(10)70258-8. Epub 2010 Nov 24. No abstract available.

PMID:
21111679
10.

[Pharmacovigilance update].

Livio F, Ivanyuk A, Biollaz J, Rothuizen L, Buclin T.

Rev Med Suisse. 2010 Jan 20;6(232):128-31. French. Erratum in: Rev Med Suisse. 2010 Jan 27;6(233):214.

PMID:
20170031
11.

Valganciclovir in adult solid organ transplant recipients: pharmacokinetic and pharmacodynamic characteristics and clinical interpretation of plasma concentration measurements.

Perrottet N, Decosterd LA, Meylan P, Pascual M, Biollaz J, Buclin T.

Clin Pharmacokinet. 2009;48(6):399-418. doi: 10.2165/00003088-200948060-00006. Review.

PMID:
19650679
12.

A LC-tandem MS assay for the simultaneous measurement of new antiretroviral agents: Raltegravir, maraviroc, darunavir, and etravirine.

Fayet A, Béguin A, Zanolari B, Cruchon S, Guignard N, Telenti A, Cavassini M, Günthard HF, Buclin T, Biollaz J, Rochat B, Decosterd LA.

J Chromatogr B Analyt Technol Biomed Life Sci. 2009 Apr 15;877(11-12):1057-69. doi: 10.1016/j.jchromb.2009.02.057. Epub 2009 Feb 28.

PMID:
19332396
13.

Population pharmacokinetics of ganciclovir in solid-organ transplant recipients receiving oral valganciclovir.

Perrottet N, Csajka C, Pascual M, Manuel O, Lamoth F, Meylan P, Aubert JD, Venetz JP, Soccal P, Decosterd LA, Biollaz J, Buclin T.

Antimicrob Agents Chemother. 2009 Jul;53(7):3017-23. doi: 10.1128/AAC.00836-08. Epub 2009 Mar 23.

14.

A single LC-tandem mass spectrometry method for the simultaneous determination of 14 antimalarial drugs and their metabolites in human plasma.

Hodel EM, Zanolari B, Mercier T, Biollaz J, Keiser J, Olliaro P, Genton B, Decosterd LA.

J Chromatogr B Analyt Technol Biomed Life Sci. 2009 Apr 1;877(10):867-86. doi: 10.1016/j.jchromb.2009.02.006. Epub 2009 Feb 11.

PMID:
19249251
15.

[Pharmacovigilance and teratovigilance 2008].

Livio F, Ivanyuk A, Biollaz J.

Rev Med Suisse. 2009 Jan 14;5(186):130-4. French.

PMID:
19238932
16.

"Iatrogenicity cascade": doing harm by treating harm?

Wagner CC, Biollaz J, Zeitlinger M, Buclin T.

Wien Med Wochenschr. 2009;159(1-2):53-7. doi: 10.1007/s10354-008-0579-y.

PMID:
19225736
17.

Pharmacogenetics-based population pharmacokinetic analysis of efavirenz in HIV-1-infected individuals.

Arab-Alameddine M, Di Iulio J, Buclin T, Rotger M, Lubomirov R, Cavassini M, Fayet A, Décosterd LA, Eap CB, Biollaz J, Telenti A, Csajka C; Swiss HIV Cohort Study.

Clin Pharmacol Ther. 2009 May;85(5):485-94. doi: 10.1038/clpt.2008.271. Epub 2009 Feb 18.

PMID:
19225447
18.

[Renal function estimation by MDRD equation: interest and limitations for drug dosing].

Livio F, Biollaz J, Burnier M.

Rev Med Suisse. 2008 Nov 26;4(181):2596-600. Review. French.

PMID:
19066149
19.

[Pharmacogenetic testing: soon before every prescription?].

Buclin T, Colombo S, Biollaz J.

Rev Med Suisse. 2008 Jul 16;4(165):1666-70. Review. French.

PMID:
18767293
20.

[Principles of therapeutic drug monitoring].

Widmer N, Csajka C, Werner D, Grouzmann E, Decosterd LA, Eap CB, Biollaz J, Buclin T.

Rev Med Suisse. 2008 Jul 16;4(165):1644-8. Review. French.

PMID:
18767290
21.

[Those words don't speak...Aprotinin and erythropoiesis stimulant agents, therapeutic use and adverse effects].

Biollaz J, Dayer P.

Rev Med Suisse. 2008 Jul 16;4(165):1635-6. French. No abstract available.

PMID:
18767288
22.

Determination of unbound antiretroviral drug concentrations by a modified ultrafiltration method reveals high variability in the free fraction.

Fayet A, Béguin A, de Tejada BM, Colombo S, Cavassini M, Gerber S, Eap CB, Telenti A, Buclin T, Biollaz J, Decosterd LA.

Ther Drug Monit. 2008 Aug;30(4):511-22. doi: 10.1097/FTD.0b013e3181817318. Erratum in: Ther Drug Monit. 2010 Feb;32(1):117.

PMID:
18641538
23.

Relationship of imatinib-free plasma levels and target genotype with efficacy and tolerability.

Widmer N, Decosterd LA, Leyvraz S, Duchosal MA, Rosselet A, Debiec-Rychter M, Csajka C, Biollaz J, Buclin T.

Br J Cancer. 2008 May 20;98(10):1633-40. doi: 10.1038/sj.bjc.6604355. Epub 2008 May 6.

24.

[Pharmacovigilance update].

Livio F, Buclin T, Biollaz J.

Rev Med Suisse. 2008 Jan 16;4(140):150-4. Review. French.

PMID:
18309879
25.

Imatinib metabolite profiling in parallel to imatinib quantification in plasma of treated patients using liquid chromatography-mass spectrometry.

Rochat B, Fayet A, Widmer N, Lahrichi SL, Pesse B, Décosterd LA, Biollaz J.

J Mass Spectrom. 2008 Jun;43(6):736-52. doi: 10.1002/jms.1369.

PMID:
18286663
26.

Misleading tacrolimus concentration value in blood taken from a catheter used for tacrolimus administration.

Grouzmann E, Buclin T, Biollaz J.

Am J Health Syst Pharm. 2008 Feb 1;65(3):226-8. doi: 10.2146/ajhp070054.

PMID:
18216007
27.

Effect of dronedarone on renal function in healthy subjects.

Tschuppert Y, Buclin T, Rothuizen LE, Decosterd LA, Galleyrand J, Gaud C, Biollaz J.

Br J Clin Pharmacol. 2007 Dec;64(6):785-91. Epub 2007 Jul 27.

28.

[Pharmacovigilance and teratovigilance].

Livio F, Buclin T, Biollaz J.

Rev Med Suisse. 2007 Jan 24;3(95):238-42. Review. French.

PMID:
17357693
29.

Determination of aciclovir and ganciclovir in human plasma by liquid chromatography-spectrofluorimetric detection and stability studies in blood samples.

Perrottet N, Beguin A, Meylan P, Pascual M, Manuel O, Buclin T, Biollaz J, Decosterd LA.

J Chromatogr B Analyt Technol Biomed Life Sci. 2007 Jun 1;852(1-2):420-9. Epub 2007 Feb 3.

PMID:
17303480
30.

Gliptins.

Grouzmann E, Buclin T, Biollaz J.

Lancet. 2007 Jan 27;369(9558):269. No abstract available.

PMID:
17258657
31.

Orosomucoid (alpha1-acid glycoprotein) plasma concentration and genetic variants: effects on human immunodeficiency virus protease inhibitor clearance and cellular accumulation.

Colombo S, Buclin T, Décosterd LA, Telenti A, Furrer H, Lee BL, Biollaz J, Eap CB; Swiss HIV Cohort Study.

Clin Pharmacol Ther. 2006 Oct;80(4):307-18.

PMID:
17015049
32.

Population pharmacokinetics of atazanavir in patients with human immunodeficiency virus infection.

Colombo S, Buclin T, Cavassini M, Décosterd LA, Telenti A, Biollaz J, Csajka C.

Antimicrob Agents Chemother. 2006 Nov;50(11):3801-8. Epub 2006 Aug 28.

33.

Population pharmacokinetics of imatinib and the role of alpha-acid glycoprotein.

Widmer N, Decosterd LA, Csajka C, Leyvraz S, Duchosal MA, Rosselet A, Rochat B, Eap CB, Henry H, Biollaz J, Buclin T.

Br J Clin Pharmacol. 2006 Jul;62(1):97-112. Erratum in: Br J Clin Pharmacol. 2010 Aug;70(2):316.

34.

Are plasma levels valid surrogates for cellular concentrations of antiretroviral drugs in HIV-infected patients?

Colombo S, Telenti A, Buclin T, Furrer H, Lee BL, Biollaz J, Decosterd LA; Swiss HIV Cohort Study.

Ther Drug Monit. 2006 Jun;28(3):332-8.

PMID:
16778716
35.

[Will good clinical practice domesticate human research?].

Buclin T, Burnand B, Biollaz J.

Rev Med Suisse. 2006 Apr 12;2(61):992-6. Review. French.

PMID:
16686333
36.

[Risk of overtreatment: not to be neglected. The example of antiepileptic drugs].

Rothuizen LE, Buclin T, Reichhart M, Biollaz J.

Rev Med Suisse. 2006 Apr 12;2(61):976-80. Review. French.

PMID:
16686330
37.

[Generic drugs and legal incentives: which impact?].

Livio F, Buclin T, Pannatier A, Biollaz J.

Rev Med Suisse. 2006 Apr 12;2(61):966-9. French.

PMID:
16686328
38.

[Prescription without authorization to market: in whose interest?].

Dayer P, Biollaz J.

Rev Med Suisse. 2006 Apr 12;2(61):963-4. French. No abstract available.

PMID:
16686327
39.

[Generic drug prescribing: pilot study on the impact of the new drug pricing system on costs and potential savings].

Wasserfallen JB, Shimia S, Biollaz J, Pannatier A.

Rev Med Suisse. 2006 Mar 29;2(59):865-6, 868-71. French.

PMID:
16646370
40.

Ritonavir-boosted atazanavir-lopinavir combination: a pharmacokinetic interaction study of total, unbound plasma and cellular exposures.

Colombo S, Buclin T, Franc C, Guignard N, Khonkarly M, Tarr PE, Rochat B, Biollaz J, Telenti A, Decosterd LA, Cavassini M.

Antivir Ther. 2006;11(1):53-62.

PMID:
16518960
41.

[Trends in drug therapy].

Livio F, Buclin T, Biollaz J.

Rev Med Suisse. 2006 Jan 11;2(48):155-9. Review. French.

PMID:
16463801
42.

Determination of the novel non-peptidic HIV-protease inhibitor tipranavir by HPLC-UV after solid-phase extraction.

Colombo S, Béguin A, Marzolini C, Telenti A, Biollaz J, Decosterd LA.

J Chromatogr B Analyt Technol Biomed Life Sci. 2006 Feb 17;832(1):138-43. Epub 2005 Dec 15.

PMID:
16359932
43.

The importance of assessing the dose actually administered in pharmacokinetic trials.

Buclin T, Perrottet N, Biollaz J.

Clin Pharmacol Ther. 2005 Apr;77(4):235-40. Review. No abstract available.

PMID:
15903121
44.

[The blood-brain barrier: recent insights].

Buclin T, Biollaz J.

Rev Med Suisse. 2005 Apr 6;1(14):959-63. Review. French.

PMID:
15898681
45.

[Multiple diseases: should we treat them all?].

Biollaz J, Buclin T.

Rev Med Suisse. 2005 Apr 6;1(14):941-7. Review. French.

PMID:
15898678
46.

[Stand up, colleagues!].

Dayer P, Biollaz J.

Rev Med Suisse. 2005 Apr 6;1(14):931. French. No abstract available.

PMID:
15898676
47.

Influence of CYP2B6 polymorphism on plasma and intracellular concentrations and toxicity of efavirenz and nevirapine in HIV-infected patients.

Rotger M, Colombo S, Furrer H, Bleiber G, Buclin T, Lee BL, Keiser O, Biollaz J, Décosterd L, Telenti A; Swiss HIV Cohort Study.

Pharmacogenet Genomics. 2005 Jan;15(1):1-5.

PMID:
15864119
48.
49.

Molecular and clinical determinants of drug-induced long QT syndrome: an iatrogenic channelopathy.

Abriel H, Schläpfer J, Keller DI, Gavillet B, Buclin T, Biollaz J, Stoller R, Kappenberger L.

Swiss Med Wkly. 2004 Nov 27;134(47-48):685-94. Review.

50.

Effect of a new angiotensin converting enzyme inhibitor MK 421 and its lysine analogue on the components of the renin system in healthy subjects. 1981.

Brunner DB, Desponds G, Biollaz J, Keller I, Ferber F, Gavras H, Brunner HR, Schelling JL.

Br J Clin Pharmacol. 2004 Dec;58(7):S778-84; discussion S785-7. No abstract available.

Supplemental Content

Loading ...
Support Center